In the prospective post-authorization safety study (PASS) of cilta-cel in relapsed/refractory multiple myeloma, which neurotoxicity finding was reported?
About 5% of patients developed cranial nerve palsy, which was easily managed with steroids, and parkinsonian-like syndrome was very rare
About 15% of patients developed parkinsonian-like syndrome, considerably higher than reported in CARTITUDE-4
Cranial nerve palsy was not seen, but immune effector cell-associated colitis occurred in about a quarter of patients